Dengvaxia US Pregnancy Registry

RecruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions

Dengue Virus Infection

Interventions

BIOLOGICAL

Dengue Tetravalent Vaccine, Live

Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous

Trial Locations (1)

RECRUITING

Investigational Site, San Juan

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY